论文部分内容阅读
前段时间,有媒体称,德国西门子公司旗下医疗器械部门因涉嫌向中国内地医院行贿而受到调查。这一消息尽管被否认,但照例引发了境外媒体关于中国政府对外资企业态度的揣测和解读。两年多来,中国反腐败行动举世瞩目。许多人注意到,中国打击“洋老虎”也毫不手软。目前已经有葛兰素史克、阿斯利康、赛诺菲、优时比等多家外资药企因涉嫌商业贿赂而受到调查。有西方媒体由此断言,在华
Some time ago, some media said that the medical device department of Germany’s Siemens Company was investigated for being suspected of bribing the Chinese mainland hospitals. Although this news was denied, it has, as usual, triggered speculation and interpretation by overseas media of the Chinese government’s attitude toward foreign-funded enterprises. Over the past two years, China’s anti-corruption campaign has drawn worldwide attention. Many people noticed that China cracked down on “foreign tigers.” There are already many foreign pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Sanofi, UBS and other foreign companies being investigated for alleged commercial bribery. There are Western media assert that in China